Familiar Mediterranean fever (FMF), an inherited autosomal recessive disorder, is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1-3 days. Patients may develop renal amyloidosis, arthritis, serositis, dermatologic and oral lesions. Diagnosis is based on clinical features, response to treatment with colchicine, and genetic analysis. Colchicine prevents attacks, renal amyloidosis and reverses proteinuria. Non-responders may receive novel therapy including IL-1 receptor antagonists and IL-1 decoy receptor. Recently, new options have been considered.Clinical Pharmacology & Therapeutics (2013); accepted article preview online 18 July 2013 doi:10.1038/clpt.2013.148.
Novel Therapeutics for the Treatment of Familial Mediterranean Fever: From Colchicine to Biologics
Bonfrate L;PALASCIANO, Giuseppe;PORTINCASA, Piero
2013-01-01
Abstract
Familiar Mediterranean fever (FMF), an inherited autosomal recessive disorder, is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1-3 days. Patients may develop renal amyloidosis, arthritis, serositis, dermatologic and oral lesions. Diagnosis is based on clinical features, response to treatment with colchicine, and genetic analysis. Colchicine prevents attacks, renal amyloidosis and reverses proteinuria. Non-responders may receive novel therapy including IL-1 receptor antagonists and IL-1 decoy receptor. Recently, new options have been considered.Clinical Pharmacology & Therapeutics (2013); accepted article preview online 18 July 2013 doi:10.1038/clpt.2013.148.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
